PRIMARY STUDY

Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Key Findings:  In this meta-analyses the authors review 6 randomized controlled trials on cannabinoid-based therapeutics in the treatment of inflammatory bowel disease. The authors concluded that cannabinoid-based therapeutics (as adjuvant therapy) may increase the chances of success for standard therapy of Crohn’s Disease, while its usage in ulcerative colitis was not recommended. Of note, the authors highlight that low-dose treatment may be more effective than higher dosages.

Data also suggest given the current scientific information that oral CBD to be the most optimal administration route.